Kardigan Completes KATALYST-AV Enrollment, Pushes Primary Endpoint to Week 48
KARD sits 27% above its 52-week low of $12.23.
Summary
Kardigan finished enrolling 156 patients in the Phase 2b KATALYST-AV trial of ataciguat in aortic stenosis, a foundational step for its lead cardiovascular program. The company amended the protocol to assess the primary aortic valve calcium endpoint at Week 48 instead of earlier, citing wide baseline calcium variability (320 to 1,983 Agatston units) that requires more time to detect a treatment effect versus placebo. A Week 24 internal interim analysis will check progression rates and mechanistic trends, and the amendment was made blinded without any safety finding. Supporting it, a real-world analysis of roughly 45,000 mild-to-moderate AS patients showed about 27% progressed rapidly and that cardiac damage markers predict faster progression, which will shape Phase 3 enrollment criteria. The tradeoff is timing: Phase 3 plans now slip to the first half of 2027 and Week 48 topline data to the second half of 2027, so the next hard readout is more than a year out. An investor webcast is set for Saturday, November 7, 2026 at 8:00 AM ET with the baseline and real-world data.
At the time of this announcement, KARD was trading at $15.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $12.23 to $27.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.